Conference Coverage

Complete Conference Coverage

Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate

Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate

Previous analysis of the SWOG S0230/POEMS study suggested that goserelin improves survival rates, ovarian function, and raises the likelihood of pregnancy among patients with hormone receptor-negative disease.

Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration

Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration

Researchers pooled results from 3 studies, which included 5114 patients with HER2-positive disease, to determine whether 1-year adjuvant trastuzumab yields the optimal OS, DFS, and rate of cardiac events.

Metformin May Not Improve pCR Rate in HER2-positive Breast Cancer

Metformin May Not Improve pCR Rate in HER2-positive Breast Cancer

Researchers randomly assigned 84 women with HER2-positive breast cancer to receive metformin plus chemotherapy with trastuzumab or chemotherapy with trastuzumab alone.

Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer

Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer

Metastatic TN and hormone receptor-positive disease is incurable and new therapy options are badly needed.

Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival

Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival

Researchers attempted to determine factors associated with DSS after patients with metastatic disease undergo surgical resection.

Olaratumab Monotherapy Benefits Patients With Soft Tissue Sarcoma Post-chemotherapy

Olaratumab Monotherapy Benefits Patients With Soft Tissue Sarcoma Post-chemotherapy

Researchers presented olaratumab monotherapy subgroup results from a phase 2 trial of patients who were previously treated with olaratumab plus doxorubicin or doxorubicin alone.

Vitamin D Supplementation Recommended for Pediatric Patients With Sarcoma

Vitamin D Supplementation Recommended for Pediatric Patients With Sarcoma

Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.

More Than 25% of Patients With Sarcoma Have Anxiety or Depression

More Than 25% of Patients With Sarcoma Have Anxiety or Depression

Researchers at the Seattle Cancer Care Alliance used email and web screening to determine patient quality of life and psychological comorbidities after a sarcoma diagnosis.

Exercise May Mitigate Doxorubicin-related Cardiotoxicity

Exercise May Mitigate Doxorubicin-related Cardiotoxicity

Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.

Several Factors Predict Recurrence, Survival Among Patients With Pelvic Ewing Sarcoma

Several Factors Predict Recurrence, Survival Among Patients With Pelvic Ewing Sarcoma

As the disease's location can make localized treatment difficult, factors that predict for LR and OS may be helpful for treatment decision-making.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs